Established in 26 countries, with market share topping 90% in Spain and sales beating targets in Italy

Device lineup diversifies with multiple dose options and an autoinjector

Celltrion's booth at the 2026 European Respiratory Society Congress, held in Barcelona, Spain, from Saturday through Wednesday (local time). (Courtesy of Celltrion)
Celltrion's booth at the 2026 European Respiratory Society Congress, held in Barcelona, Spain, from Saturday through Wednesday (local time). (Courtesy of Celltrion)

Celltrion's omalizumab biosimilar Omlyclo showcased its differentiated product convenience to court local physicians at Europe's largest respiratory conference.

Celltrion said Thursday that it took part in the 2026 European Respiratory Society (ERS) Congress, held in Barcelona, Spain, from Saturday through Wednesday (local time). At the event, it highlighted Omlyclo's clinical value and device competitiveness. The ERS Congress is Europe's largest respiratory conference, bringing together about 20,000 respiratory specialists and researchers from around the world to share the latest findings.

Omlyclo, a treatment for chronic spontaneous urticaria and allergic asthma, has been supplied in 26 countries since its European launch in late last year. In Spain, its market share is estimated to have surpassed 90 percent as of July, and in Italy sales have exceeded the company's initial targets. Prescriptions are expanding rapidly across major Southern European markets.

At the congress, Celltrion ran its booth under the slogan "Similar, but Different," emphasizing that the biosimilar's equivalence to the original product translates into greater convenience in real-world clinical settings. Omlyclo comes in three dose options — 75 milligrams, 150 milligrams and 300 milligrams — and supports multiple delivery devices, including a pre-filled syringe (PFS) and an autoinjector (AI) for easier self-administration. Its latex-free safety design and room-temperature storage convenience also drew praise.

At an expert symposium held during the congress, Roland Buhl, a professor at the University of Mainz in Germany and a leading global authority on asthma, presented data on the long-term clinical safety of omalizumab and the fiscal savings biosimilars can bring to national health care systems. The presentation drew strong interest from clinicians, coinciding with the seasonal surge in pediatric asthma cases in autumn.

Having already secured an early lead in market share in Spain and other key markets, Celltrion is now targeting major scientific conferences to move beyond price-based competition. The company aims to solidify prescription switching among local specialists through differentiated formulations, dosing options and academic marketing, backed by its direct sales operations.

Building on those gains in major markets, Celltrion plans to expand its participation in national tenders across Europe and strengthen its direct sales network with large local hospitals. The company will also take part in the Global Urticaria Forum (GUF 2026) in Berlin in December, aiming to expand Omlyclo's prescription base beyond asthma into skin disease treatment.

"We are expanding supply across Europe, building on the market penetration we have confirmed in Spain and Italy," a Celltrion official said. "We will organically link our differentiated product capabilities with our direct sales network to establish Omlyclo as one of Celltrion's core earnings drivers."


silverpaper@heraldcorp.com